trastuzumab,pertuzumab
roche
[]
phergain study: 3y idfs without cht in pet responders 98.8%.
elegant and beautiful strategy evaluating de-escalation therapy for her2+ ebc excellent presentation! bravo javi!! #asco23 
Medical Oncologist. Breast Cancer. 🏥 Ramón y Cajal University Hospital (Madrid) 🏥 Ruber Internacional Hospital (Madrid)